Dosing MDD Therapies in Medically Complex Patients: Metabolism and Interactions

"Dosing MDD Therapies in Medically Complex Patients: Metabolism and Interactions" takes up the point where caution and urgency pull in opposite directions.

Dr. Alva notes that starting low and going slow collides with therapeutic urgency more often than the guidelines admit. He asks Dr. DeBattista to walk through dosing differences across classes, and where comorbidities force a prescriber's hand.

Dr. DeBattista calls it a big question and starts with hepatic metabolism and the cytochrome P450 system. A patient with cirrhosis or liver disease has a harder time clearing these agents, which can produce toxicity. He points to duloxetine as an example carrying hepatic considerations, and separately to renally cleared agents that become a problem in compromised kidney function. He then makes the interaction picture explicit. Several of the agents already discussed are substrates as well as inhibitors, and sometimes inducers, of the P450 system. That matters because patients take many medications, not only psychiatric ones. SSRIs remain the most commonly prescribed class, in part because the starting dose is a therapeutic dose. But he offers two concrete failure modes. A patient on tamoxifen who is taking paroxetine may run into trouble, because the tamoxifen cannot be metabolized properly. A patient on a statin dependent on CYP3A4 or CYP2C19 may not metabolize the statin efficiently, and can develop complications from it.

Dr. DeBattista emphasizes that these considerations differ meaningfully from class to class, and even within a class. He offers that as the explanation for a pattern many clinicians recognize in themselves. Colleagues tend to stay with a small number of medications, sometimes only a few within the SSRI class. Those prescribers know the interaction profile of their small set, which means fewer surprises and safer prescribing for their particular patients. The implication he leaves is that familiarity is itself a safety strategy, and that expanding a personal formulary requires learning the interaction map that comes with it.

Up next, in "MDD Side Effect Profiles: Counseling, Adherence, and Suicidality Monitoring," the experts take on the side effects that end treatment before it has a chance to work.